COST EFFECTIVENESS OF LENVATINIB, SORAFENIB, AND PLACEBO IN TREATMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1307
https://www.valueinhealthjournal.com/article/S1098-3015(16)01375-9/fulltext
Title :
COST EFFECTIVENESS OF LENVATINIB, SORAFENIB, AND PLACEBO IN TREATMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01375-9&doi=10.1016/j.jval.2016.03.1307
First page :
A204
Section Title :
Diabetes/Endocrine Disorders - Cost Studies
Open access? :
No
Section Order :
647